Clinical trial · Observational
MOST: Mediterranean Oncology Senior Tests
Longitudinal Study Comparing Markers of Frailty in Geriatric Assessment to Detect Vulnerability to Chemotherapy in Patients Aged 70 Years or Older With Colon Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
MOST is a longitudinal study whose aim is to test the hypothesis that frailty markers are better at detecting vulnerable patients and that they are a better "Adverse Events" predictive tool than the CGA (Comprehensive Geriatric Assessment) in older cancer patients referred for chemotherapy. The second hypothesis is that a brief screening tool based on a combination of some frailty markers and some used in the CGA would help the oncologist detect patients requiring a more complete geriatric assessment
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Aged 70 or Older | — | UNRESOLVED | — |
| Colon Cancer Patients Receiving Chemotherapy in the Adjuvant or Metastatic Setting | Colon Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Frailty markers | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Comprehensive Geriatric Assessment (CGA)
- description
- Functional status, Comorbidities, Objective physical performance, Nutrition, Cognition, Depression, Social support
- interventionNames
- Other: Frailty markers
Primary outcomes (1)
- measure
- Occurrence of Adverse Events
- timeFrame
- up to 18 months
- description
- The primary endpoint analysis is defined by the relationship between the CGA (Comprehensive Geriatric Assessment) and frailty markers on the one hand and the occurrence of adverse events on the other. The effect of each tool will be evaluated using a Cox model. The results will be adjusted on the main prognostic factors (age, type and stage of cancer).
Secondary outcomes (1)
- measure
- Performance of the brief screening tool
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with colon cancer with or without metastases * Age ≥ 70 years * Patients did not start chemotherapy yet Exclusion Criteria: * Patients terminally ill with a life expectancy \<3 months * Patients who have started chemotherapy or hormonal therapy
References
Publications (2)
- BACKGROUNDRetornaz F, Seux V, Sourial N, Braud AC, Monette J, Bergman H, Soubeyrand J. Comparison of the health and functional status between older inpatients with and without cancer admitted to a geriatric/internal medicine unit. J Gerontol A Biol Sci Med Sci. 2007 Aug;62(8):917-22. doi: 10.1093/gerona/62.8.917. PMID 17702885
- BACKGROUNDRetornaz F, Monette J, Batist G, Monette M, Sourial N, Small D, Caplan S, Wan-Chow-Wah D, Puts MT, Bergman H. Usefulness of frailty markers in the assessment of the health and functional status of older cancer patients referred for chemotherapy: a pilot study. J Gerontol A Biol Sci Med Sci. 2008 May;63(5):518-22. doi: 10.1093/gerona/63.5.518. PMID 18511757